-
Multiple Myeloma Market Updates : to Grow at a CAGR of 10.5% from 2022 to 2031 ; Predicted to Surge in Demand by 2031
29 Mar 2024 08:13 GMT
… multiple myeloma drugs
Opportunities
Increase in the number of multiple myeloma drug … of treatments for multiple myeloma, including drugs, immunotherapy … effects of multiple myeloma medications like Kyprolis, … AG, Teva Pharmaceutical Industries, Johnson …
-
Irish research discovers potential new multiple myeloma treatment
29 Mar 2024 09:41 GMT
… treatment combination for one of the most difficult-to-treat … medication currently approved for leukaemia, has benefits for patients with multiple myeloma … new drug combination is a promising development. Our … for multiple myeloma in a clinical trial setting …
-
ORIC Pharmaceuticals: Rally Seems Overdone
29 Mar 2024 11:15 GMT
… of cancer resistance concern ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) have seen … biopharmaceutical concern focused on the development of therapies that counter resistance … bispecific antibody for the treatment of multiple myeloma. That trial may not come to …
-
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
29 Mar 2024 05:54 GMT
… -5339 received Clinical Trial Application approval from … FDA granted orphan drug designation, for BI-1206, for the treatment … developing CID-103 for the treatment of patients with multiple myeloma. … wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd …
-
Bristol Myers Squibb’s Abecma approved in European Union in earlier lines for triple-class exposed relapsed and refractory multiple myeloma
28 Mar 2024 22:47 GMT
… shift in the treatment paradigm.”
The current treatment paradigm for multiple myeloma includes IMiDs … .S. Food and Drug Administration (FDA). The FDA’s Oncologic Drugs Advisory Committee (ODAC …
-
Study Finds COQ2 Essential for Multiple Myeloma Proliferation, Affects Sensitivity to Cell Death
28 Mar 2024 18:35 GMT
Multiple myeloma (MM), which is the … is a challenging disease to treat. The COQ2 gene is believed … as an Essential Gene in Multiple Myeloma (MM) Survival: The study … valuable information and insights when developing more treatment strategies for MM, according …
-
Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential
28 Mar 2024 17:01 GMT
Biodexa Pharmaceuticals BDRX, developing MTX110 for … initially used to treat multiple myeloma and received FDA approval in 2015 … says the drug achieves high drug concentrations within … trial involving newly diagnosed DMG patients showed that MTX110 treatment …
-
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
27 Mar 2024 19:22 GMT
… patients being treated for multiple myeloma (MM), a potential … the phase 3 parallel E1A11 trial (ENDURANCE; NCT01863550), which … the opinions of the FDA and previous reports, … and early treatment discontinuation among patients with multiple myeloma. JAMA Netw …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… of oncology, global clinical development, Merck Research Laboratories. … treatment. Consider monitoring more frequently as compared to when the drugs … With Multiple Myeloma
In trials in patients with multiple myeloma, … _pi.pdf and Medication Guide for KEYTRUDA …
-
Oncopeptides joins up with Vector to commercialize blood cancer drug Pepaxto in the Middle East, North Africa
27 Mar 2024 18:54 GMT
… with the FDA to continue the approval for Pepaxto in multiple myeloma patients … , the company announced it’s teaming up with Vector Pharma … Africa.
Vector will distribute the drug, marketed as Pepaxti outside …